Psychostimulants in the Treatment of Depression

@article{Orr2007PsychostimulantsIT,
  title={Psychostimulants in the Treatment of Depression},
  author={K. Orr and David Taylor},
  journal={CNS Drugs},
  year={2007},
  volume={21},
  pages={239-257}
}
Psychostimulants have euphoric and alerting properties that suggest their usefulness in treating depressive disorders; however, problems with tolerance and dependence with some drugs militate against their widespread therapeutic use where more acceptable licensed alternatives are available. The introduction of modafinil, a stimulant not associated with tolerance and dependence, has re-awakened interest in psychostimulants as antidepressants. The available literature, while containing somewhat… Expand
[Psychostimulants in the treatment of depression].
TLDR
Overall, data support the use of psychostimulants in depression particularly in cases of drug resistance, when there is a severe physical illness or when short-term efficiency is needed, especially in the elderly. Expand
Use of adjunctive stimulants in adult bipolar depression.
TLDR
An updated perspective on the use of stimulants and stimulant-like medications in adult bipolar depression is provided, considering not only recent randomized controlled trials, but also open naturalistic studies, in order to clarify the strengths and limitations of using these agents. Expand
Beyond ADHD and narcolepsy: psychostimulants in general
SummARy Psychostimulants (dexamphetamine, methyl­ pheni date, modafinil) reduce fatigue, promote alertness and wakefulness, and have possible mood­enhancing properties. In modern psychiatricExpand
Beyond ADHD and narcolepsy: psychostimulants in general psychiatry
TLDR
There is currently not enough evidence to recommend their routine use for general psychiatric conditions, and the recent literature regarding psychostimulant use in general and consultation-liaison psychiatry is reviewed. Expand
Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials
TLDR
Clearly larger well designed placebo-controlled studies with longer follow-up accompanied by evaluations of tolerance/dependence are warranted before psychostimulants can be recommended in routine clinical practice for the treatment of MDD. Expand
The role of methylphenidate in depression
Abstract Introduction: Depression is a burdening disease state where up to 30% of individuals do not respond to first-line treatment. Adjunctive use of psychostimulants has been investigated for theExpand
Psychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium-term evaluation of cost benefits.
TLDR
This open study suggests that psychostimulants may be efficacious antidepressant options for managing unipolar and bipolar melancholia, often seemingly having very rapid onset and generally requiring only low doses, and arguing the need for controlled studies in melancholic patients. Expand
The role of psychostimulants in psychogeriatrics: a New Zealand survey
TLDR
To ascertain the current prescribing practices of psychostimulants by psychogeriatricians in New Zealand, a large number of doctors believe that dexamphetamine, methylphenidate and modafinil should be considered standard treatments in major depression or other affective disorders. Expand
Dépression résistante : les autres stratégies thérapeutiques
TLDR
Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression and requires careful monitoring of drug interactions and dietary restrictions. Expand
Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.
TLDR
It is suggested that adjunctive use of methylphenidate can be a therapeutic option in treating some patients with psychotic unipolar depression who do not adequately respond to the combination treatment of an antidepressant and an atypical antipsychotic. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Modafinil monotherapy in depression
TLDR
This report describes the first case in which modafinil was utilized as monotherapy treatment of depression, a novel psychostimulant that has shown efficacy in, and was recently marketed for, treating daytime sleepiness associated with narcolepsy. Expand
Modafinil augmentation of antidepressant treatment in depression.
TLDR
Modafinil appears to be a drug with promise as an augmenter of antidepressants, especially in patients with residual tiredness or fatigue, and is a particularly attractive alternative to other stimulants because of its low abuse potential and Schedule IV status. Expand
d-Amphetamine versus methylphenidate effects in depressed inpatients
BACKGROUND: Both d-amphetamine and methylphenidate cause similar behavioral and subjective effects and can relieve depressive symptoms in some patients. However, the neurochemical effects ofExpand
CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.
TLDR
With properly motivated and complaint patients and careful clinical monitoring by the prescribing psychiatrist, stimulant potentiation of MAOIs may be a viable option for treatment-resistant depressed patients. Expand
Use of Psychostimulants in Medically Ill Patients with Neurological Disease and Major Depression
TLDR
The effective therapeutic response to dextroamphetamine and methylphenidate by five depressed patients with neurological disease is described, and there was a rapid remission of depressive symptomatology with no adverse side effects. Expand
An open study of methylphenidate in bipolar depression.
TLDR
In this brief, open study, methylphenidate was effective and relatively safe in depressed bipolar subjects and was shown to reduce manic behavior. Expand
Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92)
TLDR
Modafinil appears to be an appropriate augmentation to antidepressant treatment, leading to a remission rate of 43%. Expand
Can long-term treatment with antidepressant drugs worsen the course of depression?
  • G. Fava
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2003
TLDR
The possibility that antidepressant drugs may worsen the course of depression needs to be tested, even though its scientific exploration is likely to encounter considerable methodological and ideological difficulties. Expand
Efficacy and side effects of methylphenidate for poststroke depression.
TLDR
Results of this methylphenidate trial for post stroke depression in elderly patients suggest that it is a safe and effective treatment for poststroke depression. Expand
Methylphenidate in depressed medically ill patients.
TLDR
Methylphenidate provides a safe and effective alternative to tricyclic antidepressants in medically ill populations but appears to be less effective in the presence of delirium. Expand
...
1
2
3
4
5
...